Chidamide is a histone deacetylase (HDAC) inhibitor that is currently used to treat cutaneous T-cell lymphoma in clinic. Herein nicotinamide phosphoribosyltransferase (NAMPT) was identified to be a new target of chidamide on the basis of the pharmacophore analysis, molecular docking, biological assays, inhibitor design, and structure-activity relationship study. The polypharmacology of chidamide will provide important information for better understanding its antitumor mechanism. Also, design of dual NAMPT/HDAC inhibitors may serve as an effective strategy to develop novel antitumor agents.

中文翻译：

---

烟酰胺磷酸核糖基转移酶（NAMPT）是抗肿瘤药物Chidamide的新目标。

Chidamide是一种组蛋白脱乙酰基酶（HDAC）抑制剂，目前在临床上用于治疗皮肤T细胞淋巴瘤。在此，基于药效团分析，分子对接，生物学分析，抑制剂设计和结构-活性关系研究，烟酰胺磷酸核糖基转移酶（NAMPT）被确定为几丁质的新靶标。Chidamide的多药理学将为更好地了解其抗肿瘤机制提供重要信息。而且，双重NAMPT / HDAC抑制剂的设计可以作为开发新型抗肿瘤剂的有效策略。